CA2718943A1 - Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists - Google Patents

Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists Download PDF

Info

Publication number
CA2718943A1
CA2718943A1 CA2718943A CA2718943A CA2718943A1 CA 2718943 A1 CA2718943 A1 CA 2718943A1 CA 2718943 A CA2718943 A CA 2718943A CA 2718943 A CA2718943 A CA 2718943A CA 2718943 A1 CA2718943 A1 CA 2718943A1
Authority
CA
Canada
Prior art keywords
opioid
antagonist
prodrug
opioid agonist
abuse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2718943A
Other languages
English (en)
French (fr)
Inventor
Audra Lynn Stinchcomb
Stan Lee Banks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zynerba Pharmaceuticals Inc
Original Assignee
Alltranz Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltranz Inc filed Critical Alltranz Inc
Publication of CA2718943A1 publication Critical patent/CA2718943A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2718943A 2008-03-26 2009-03-26 Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists Abandoned CA2718943A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3976308P 2008-03-26 2008-03-26
US61/039,763 2008-03-26
PCT/US2009/038439 WO2009120889A2 (en) 2008-03-26 2009-03-26 Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists

Publications (1)

Publication Number Publication Date
CA2718943A1 true CA2718943A1 (en) 2009-10-01

Family

ID=40809924

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2718943A Abandoned CA2718943A1 (en) 2008-03-26 2009-03-26 Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists

Country Status (6)

Country Link
US (1) US20090246265A1 (enExample)
EP (1) EP2254561A2 (enExample)
JP (1) JP2011515495A (enExample)
CA (1) CA2718943A1 (enExample)
MX (1) MX2010010512A (enExample)
WO (1) WO2009120889A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4458376A4 (en) * 2022-01-30 2025-05-07 Zhejiang University PH-REACTIVE ANALGESIC FOR TARGETING DAMAGED DORSAL ROOT GANGLION SEGMENT AND USE THEREOF

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
CA2734333A1 (en) * 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
US8386274B1 (en) 2008-09-17 2013-02-26 Mckesson Financial Holdings Limited Systems and methods for a prescription safety network utilizing eligibility verification transactions
CA2795158C (en) * 2010-04-02 2019-10-22 Alltranz Inc. Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
US8392219B1 (en) 2010-05-10 2013-03-05 Mckesson Financial Holdings Limited Systems and methods for streamlined patient enrollment for one or more healthcare programs
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
GB2483579A (en) * 2010-06-30 2012-03-14 Londonpharma Ltd Sublingual formulations comprising methadone and ethanol for use in reducing pain
WO2012119151A2 (en) * 2011-03-03 2012-09-07 Saia Mark Stephen Method and apparatus for alcohol administration
US9566341B1 (en) 2011-04-27 2017-02-14 University Of Kentucky Research Foundation Compounds including Cox inhibitor moiety and enhanced delivery of active drugs using same
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
AU2012286843A1 (en) * 2011-07-28 2014-02-20 Patricia J. Mclaughlin Methods and compositions for treatment of epithelial wounds
TWI522101B (zh) 2012-04-17 2016-02-21 普渡製藥有限合夥事業 處理由類鴉片引起之不利的藥效動力反應之系統和方法
US20140170593A1 (en) * 2012-12-18 2014-06-19 Oltuse, Llc Patch for non-invasive pain relief
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9839611B2 (en) 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
EP3043777B1 (en) 2013-09-10 2020-04-22 Fresh Cut Development, LLC Sublingual buprenorphine spray
US9918981B2 (en) 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
US9867818B2 (en) 2013-09-10 2018-01-16 Insys Development Company, Inc. Sublingual buprenorphine spray
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016007245A1 (en) 2014-07-08 2016-01-14 Insys Pharma, Inc. Sublingual naloxone spray
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
TW201613590A (en) * 2014-09-12 2016-04-16 Purdue Pharma Lp Systems and methods for attenuating opioid-induced euphoria
JP6464181B2 (ja) * 2014-10-14 2019-02-06 久光製薬株式会社 貼付剤
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
US10496793B1 (en) 2014-12-15 2019-12-03 Mckesson Corporation Systems and methods for determining eligibility in a prescription safety network program
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
EP3267875A4 (en) 2015-03-12 2018-12-05 Chrono Therapeutics Inc. Craving input and support system
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
GB201520390D0 (en) * 2015-11-19 2016-01-06 Euro Celtique Sa Composition
WO2017164084A1 (ja) * 2016-03-24 2017-09-28 株式会社メドレックス 誤用防止特性を有する貼付製剤
EP3528804B1 (en) * 2016-10-20 2023-07-26 APIRX Pharmaceutical USA, LLC Chewing gum composition comprising cannabinoids and opioid agonists and/or antagonists
JP6865235B2 (ja) * 2016-12-28 2021-04-28 久光製薬株式会社 ブトルファノール含有貼付剤
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
WO2018198924A1 (ja) 2017-04-25 2018-11-01 久光製薬株式会社 貼付剤
US10898448B2 (en) 2017-04-25 2021-01-26 Hisamitsu Pharmaceutical Co., Inc. Patch
CA3068036A1 (en) 2017-06-30 2019-01-03 Purdue Pharma L.P. Use to buprenorphine in combination with an opioid to treat pain
EP3703694A4 (en) 2017-11-03 2021-08-18 Nirsum Laboratories, Inc. MEDICINES ANTAGONISTS OF OPIOID RECEPTORS
JP7837672B2 (ja) * 2017-12-14 2026-03-31 エルテーエス ローマン テラピー－ジステーメ アーゲー 塩形態の有効成分を含むマイクロニードルアレイ
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
KR102898979B1 (ko) * 2018-12-27 2025-12-10 에일러 파마슈티컬스 아이엔씨. 주사가능한 날트렉손 서방형 약학 제제
EP3965765A4 (en) 2019-05-07 2023-01-04 Nirsum Laboratories, Inc. OPIOID RECEPTOR ANTAGONIST PRODRUGS
WO2023022050A1 (ja) * 2021-08-17 2023-02-23 株式会社カネカ アミノアルキルテトラヒドロピラン誘導体

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
FR2519985A1 (fr) * 1982-01-15 1983-07-22 Ugine Kuhlmann Procede perfectionne de fabrication de l'e-caprolactone
US4780320A (en) * 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US7011843B2 (en) * 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP2062573B1 (en) * 2001-05-01 2011-11-16 Euro-Celtique S.A. Abuse resistant opioid containing transdermal systems
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US6913760B2 (en) * 2001-08-06 2005-07-05 New England Medical Hospitals, Inc. Drug delivery composition
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
DE60336394D1 (de) * 2002-04-23 2011-04-28 Durect Corp Transdermale analgetische systeme mit reduziertem missbrauchspotential
DE60312160T2 (de) * 2002-06-10 2007-10-31 Euro-Celtique S.A. Entsorgungssysteme für transdermale abgabevorrichtungen zur verhinderung des missbrauchs von darin enthaltenen wirkstoffen
ATE367155T1 (de) * 2002-08-09 2007-08-15 Gruenenthal Gmbh Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin
AU2003285934A1 (en) * 2002-10-25 2004-05-25 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
MXPA05009757A (es) * 2003-03-13 2005-12-05 Controlled Chemicals Inc Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida.
US20040191301A1 (en) * 2003-03-27 2004-09-30 Van Duren Albert Philip Transdermal device having a phase change material
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
US8784874B2 (en) * 2003-09-10 2014-07-22 Noven Pharmaceuticals, Inc. Multi-layer transdermal drug delivery device
EP1677771A2 (en) * 2003-10-30 2006-07-12 Alza Corporation Transdermal analgesic systems having reduced abuse potential
LT2351555T (lt) * 2004-02-23 2016-12-27 Euro-Celtique S.A. Piktnaudžiavimui atspari priemonė, skirta transderminiam opoido įvedimui
WO2007022535A2 (en) * 2005-08-19 2007-02-22 Pharmacofore, Inc. Prodrugs of active agents
ES2761812T3 (es) * 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007070632A2 (en) * 2005-12-13 2007-06-21 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
US7511054B2 (en) * 2006-09-22 2009-03-31 Alltranz Inc. Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4458376A4 (en) * 2022-01-30 2025-05-07 Zhejiang University PH-REACTIVE ANALGESIC FOR TARGETING DAMAGED DORSAL ROOT GANGLION SEGMENT AND USE THEREOF

Also Published As

Publication number Publication date
MX2010010512A (es) 2010-11-09
WO2009120889A3 (en) 2011-01-20
JP2011515495A (ja) 2011-05-19
EP2254561A2 (en) 2010-12-01
WO2009120889A2 (en) 2009-10-01
US20090246265A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
US20090246265A1 (en) Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
CA2795158C (en) Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
CA2795156C (en) Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
CA2955247C (en) Abuse deterrent opiod/opiod-antagonist transdermal patch
US8309568B2 (en) Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
CA2679316C (en) Morphine composition for transdermal absorption, morphine composition storing unit and transdermal absorption preparation using the same
KR100742471B1 (ko) 활성 물질 디아모르핀을 포함하는 약학 제제 및 아편제중독증의 치료 방법에서의 그의 용도
US20190328681A1 (en) Transdermal patch
CA2699172A1 (en) Compositions and methods for delivery of poorly soluble drugs
CZ20023030A3 (cs) Farmaceutický prostředek
JPH04128231A (ja) ブプレノルフインを経皮的にデリバーすることからなるコ力インおよびヘロイン耽溺の治療方法
US10874658B2 (en) Sublingual opioid formulations containing naloxone

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150326